Technology Overview
There are 27 million aspirin users and 28 million Plavix users with 6.5 million new prescriptions being written each year to prevent heart attacks, strokes, blood clotting and stent occlusions. Studies show that over 20% of these individuals are poorly responsive and left unprotected. ThromboVision’s ground-breakingThrombo-Guide® platelet aggregation system.
The T-Guide® is a simple, inexpensive point-of-care test intended for doctors’ offices, clinics, and heart catheterization labs. ThromboVision believes that platelet monitoring is becoming a standard part of a patient’s cardiovascular risk factor modification program. It is expected to be an element of a patient’s routine physical—similar to standard cholesterol monitoring.
The ThromboGuide Platelet Aggregation Analyzer
measures platelet aggregation using a patented light scattering technology.
The T-Guide is currently in its developmental stage and is not commercially marketed nor FDA cleared.